Sustained release, comfort formulation for glaucoma therapy
CA 2004468 C · Owner: Alcon Laboratories Inc. · Inventors: Jani, Rajni; Harris, Robert Gregg
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are nonstinging, sustained release ophthalmic formulations to control intraocular pressure in antiglaucoma therapy comprising a basic active a, cation exchange resin, and, inter alia an acidic, mucomimetic polymer. Also disclosed are methods of treatment comprising administering such formulations topically to the eye when indicated for control and lowering for intraocular pressure.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 1, 1989 and granted October 1, 1996. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 1, 2009.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 1, 2011.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.